Company
HighLife
Paris structural-heart company founded in 2010, with a US facility in Irvine, California. Develops transcatheter mitral valves.
1 story
Regulatory News has published 1 story about HighLife on 24 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 24 September 2026.
This page is generated from Regulatory News’ editorial coverage of HighLife. It is not an advertisement.
On the record
- Company
- HighLife SAS
- Headquarters
- Paris, France, with a U.S. facility in Irvine, California
- Founded
- 2010, by Georg Börtlein with Malek Nasr, Prof. Rüdiger Lange and Dr. Nicolo Piazza
- Regulator
- CE mark under EU MDR (January 2026); FDA IDE approval for a U.S. pivotal study (June 2024)
- Latest milestone
- $90 million (€80 million) financing round
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
